FDA Approves All-Oral Leukemia Regimen for Older Patients
The two-pill treatment for newly diagnosed acute myeloid leukemia replaces regular clinic injections for eligible patients.
Updated on Nov. 11, 2026 in Cancer

The FDA has approved an all-oral two-pill regimen combining decitabine, cedazuridine, and venetoclax for older patients newly diagnosed with acute myeloid leukemia. A New England Journal of Medicine study found the regimen performs about as well as the injection-based treatment it can replace.
Why it matters
Traditional treatment required clinic visits five to seven days every month, a burden some older patients reportedly found so disruptive that they forgo treatment entirely. An oral option may make consistent treatment more feasible for patients who cannot easily travel to a clinic.
The ASCERTAIN-V Phase I-II trial enrolled 189 patients and found 47% achieved complete response, with 60% of transfusion-dependent patients no longer needing transfusions during treatment. Longer-term outcomes beyond the reported median overall survival of 15.5 months are not addressed in the available data.
The players
Yale School of Medicine
A medical school affiliated with Yale University in New Haven, Connecticut, known for its biomedical and clinical research programs.
New England Journal of Medicine
A leading peer-reviewed medical journal published by the Massachusetts Medical Society, widely regarded as one of the most influential publications in clinical medicine.
The details
The regimen replaces injections with venetoclax, which is taken on a shortened schedule of 21, 14, or seven days per cycle depending on blood count recovery, and decitabine-cedazuridine, which is reduced from five days to three to four days per cycle in later cycles. The FDA has approved the combination as a standard-of-care option for older patients or those ineligible for intensive chemotherapy.
Timeline
The FDA approval and the Yale School of Medicine publicity of the study took place on November 11, 2026.
Health Landscape
The all-oral combination builds on venetoclax, which was first approved by the FDA for acute myeloid leukemia in 2018 and became a standard component of treatment for older patients. By replacing injectable hypomethylating therapy with an oral alternative, the regimen extends that established drug's role into a fully oral treatment pathway.
Patients who previously needed frequent clinic visits for injections may be able to manage treatment at home with two daily pills, reducing travel and time away from daily life. Patients and families should discuss with their oncologist whether the regimen is appropriate given their specific health status and treatment history.
The takeaway
For older patients facing acute myeloid leukemia, an all-oral option may remove the burden of frequent clinic visits without sacrificing survival outcomes compared to injection-based care. Patients should review treatment options with their oncology team to determine suitability.
Further reading
Explore more cancer news and research across the United States.
More information
Read the full New England Journal of Medicine study on all-oral AML treatment for complete trial details.
Source note: This article includes information reported by News-Medical.






